Enveda Therapeutics received FDA IND clearance and initiated a Phase I trial of ENV‑6946, a first‑in‑class oral small molecule for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The trial will assess safety, pharmacokinetics, and early signals of target engagement. ENV‑6946’s IND and human dosing mark a milestone for a company translating natural‑product‑inspired chemistry into oral therapeutics; success in early cohorts would validate Enveda’s discovery platform and position the asset for rapid clinical progression in a competitive IBD landscape.